146 related articles for article (PubMed ID: 19070795)
41. Survival impact of integrative cancer care in advanced metastatic breast cancer.
Block KI; Gyllenhaal C; Tripathy D; Freels S; Mead MN; Block PB; Steinmann WC; Newman RA; Shoham J
Breast J; 2009; 15(4):357-66. PubMed ID: 19470134
[TBL] [Abstract][Full Text] [Related]
42. Clinical studies with anticoagulants to improve survival in cancer patients.
Gerotziafas GT; Papageorgiou C; Hatmi M; Samama MM; Elalamy I
Pathophysiol Haemost Thromb; 2008; 36(3-4):204-11. PubMed ID: 19176993
[TBL] [Abstract][Full Text] [Related]
43. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
[TBL] [Abstract][Full Text] [Related]
44. Advances in angiogenesis research: relevance to urological oncology.
Campbell SC
J Urol; 1997 Nov; 158(5):1663-74. PubMed ID: 9334575
[TBL] [Abstract][Full Text] [Related]
45. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases.
Benoist S; Nordlinger B
Ann Surg Oncol; 2009 Sep; 16(9):2385-90. PubMed ID: 19554377
[TBL] [Abstract][Full Text] [Related]
46. New results from the use of bisphosphonates in cancer patients.
Coleman R; Gnant M
Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
[TBL] [Abstract][Full Text] [Related]
47. Second-line therapy in bladder cancer.
Bachner M; De Santis M
Curr Opin Urol; 2009 Sep; 19(5):533-9. PubMed ID: 19550334
[TBL] [Abstract][Full Text] [Related]
48. EORTC-GU group expert opinion on metastatic renal cell cancer.
de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
[TBL] [Abstract][Full Text] [Related]
49. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration.
Margulis V; Shariat SF; Matin SF; Kamat AM; Zigeuner R; Kikuchi E; Lotan Y; Weizer A; Raman JD; Wood CG;
Cancer; 2009 Mar; 115(6):1224-33. PubMed ID: 19156917
[TBL] [Abstract][Full Text] [Related]
50. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
51. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
52. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy.
Nishiyama M; Eguchi H
Adv Drug Deliv Rev; 2009 May; 61(5):402-7. PubMed ID: 19133303
[TBL] [Abstract][Full Text] [Related]
54. [Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region].
Paviot BT; Bachelot T; Clavreul G; Jacquin JP; Mille D; Rodrigues JM
Bull Cancer; 2009 Oct; 96(10):929-40. PubMed ID: 19696006
[TBL] [Abstract][Full Text] [Related]
55. Comparative outcomes following endoscopic ureteral detachment and formal bladder cuff excision in open nephroureterectomy for upper urinary tract transitional cell carcinoma.
Walton TJ; Sherwood BT; Parkinson RJ; Obakponovwe O; Thomas SA; Taylor MC; England RC; Lemberger RJ
J Urol; 2009 Feb; 181(2):532-9. PubMed ID: 19084866
[TBL] [Abstract][Full Text] [Related]
56. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
Gleave M; Klotz L; Taneja SS
Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
[TBL] [Abstract][Full Text] [Related]
57. Metastasis-directed therapy among urological malignancies: where do we stand?
Re C; Stewart GD; Capitanio U
Curr Opin Urol; 2024 Jul; 34(4):258-260. PubMed ID: 38835186
[No Abstract] [Full Text] [Related]
58. [Local treatment in oligometastatic urological malignancies : evidence of wishful thinking ?].
Valerio M; Cerantola Y; Lucca I; Berthold D; Jichlinski P
Rev Med Suisse; 2017 Nov; 13(585):2083-2086. PubMed ID: 29185632
[TBL] [Abstract][Full Text] [Related]
59. Assessment of human genitourinary tumors and chemosensitivity testing in 3-dimensional collagen gel culture.
Perrapato SD; Slocum HK; Huben RP; Ghosh R; Rustum Y
J Urol; 1990 May; 143(5):1041-5. PubMed ID: 2329594
[TBL] [Abstract][Full Text] [Related]
60. [Can systemic treatment for lymph node metastases be given with curative intent?].
Gauler T; Schuler M
Urologe A; 2009 Jan; 48(1):62-5. PubMed ID: 19050846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
